Related Experiment Video
Updated: May 8, 2026

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research
Published on: November 3, 2023
Role of N-Acetylcysteine to Prevent Contrast-Induced Nephropathy: A Meta-analysis
Rohit S Loomba1, Parinda H Shah, Saurabh Aggarwal
11Children's Hospital of Wisconsin/Medical College of Wisconsin Affiliated Hospitals, Wauwatosa, WI; 2Advocate Illinois Masonic Medical Center, Chicago, IL; and 3James A. Lovell Federal Health Center/Chicago Medical School, North Chicago, IL.
Insights
N-acetylcysteine (NAC) may help prevent contrast-induced nephropathy in patients undergoing coronary angiography. However, NAC did not significantly improve creatinine levels, reduce dialysis needs, or lower mortality rates in this systematic review.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a significant risk following coronary angiography.
- The efficacy of N-acetylcysteine (NAC) in preventing CIN remains debated due to varied study designs and outcomes.
Purpose of the Study:
- To systematically evaluate the effectiveness of N-acetylcysteine (NAC) in preventing contrast-induced nephropathy (CIN).
- To analyze the impact of NAC dosage and administration route on CIN prevention and clinical outcomes.
Main Methods:
- A systematic literature search was conducted across PubMed, Ovid, and the Cochrane library.
- Studies were pooled using strict inclusion/exclusion criteria.
- Subgroup analyses were performed based on NAC dose (600 mg) and route (oral administration).
Main Results:
- Pooled analysis indicated NAC significantly favored CIN prevention in patients undergoing coronary angiography.
- No significant benefits were observed for NAC regarding pre/post-angiography creatinine levels, dialysis requirements, or all-cause mortality.
- Subgroup analyses showed no significant differences in outcomes based on NAC dose or route, except for the incidence of postcatheterization nephropathy.
Conclusions:
- N-acetylcysteine (NAC) may not significantly impact overall clinical outcomes after coronary or peripheral artery catheterization.
- The dose and route of NAC administration do not appear to influence these clinical outcomes.
- Further research may be needed to clarify the precise role of NAC in CIN prevention.
Abstract:
It is unclear whether N-acetylcysteine is useful in preventing contrast-induced nephropathy in patients undergoing coronary angiography. Because of different inclusion and exclusion criteria and different definitions of studied parameters, various studies have reported different outcomes. A systematic search was done using PubMed, Ovid, and the Cochrane library, and studies were pooled after strict inclusion and exclusion criteria. Separate analysis was conducted for all endpoints including only studies that used an N-acetylcysteine (NAC) dose of 600 mg, and another separate analysis was conducted for all endpoints including only studies that used oral route NAC to study how the dose and route of administration of NAC affect the outcomes. The results of the pooled analysis significantly favored the use of NAC to prevent contrast-induced nephropathy in patients undergoing coronary angiography but failed to show any significant benefit in terms of creatinine levels preangiography and postangiography, need for dialysis, and all-cause mortality. The effects of route and dose of NAC did not show any significant difference except in respect to incidence of postcatheterization nephropathy. This study shows that NAC may not have any impact on clinical outcomes after peripheral or coronary artery catheterization and that dose and route do not seem to have any effect on these outcomes.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury II: Pathophysiology
Cardiac Catheterization I: Pre-Procedure Overview
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management